August 2022 A NanoBRET-Based H 3 R Conformational Biosensor to Study Real-Time H 3 Receptor Pharmacology

Chris Cargill appointed as President and Chief Executive Officer • Dr.

Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris from ARPA-H’s Sprint for Women’s Health Nxera Pharma Wins Biotech Company of the Year and Financing Deal

success Sosei and PharmEnable extend neurological disease drugs hunt Sosei Heptares’ President & CEO Chris

INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease Chris

Topline Safety and Tolerability Data from Proof-of-Concept Studies Sosei Heptares’ President & CEO Chris

From the scientist’s view: a conversation with … Chris Tate AI is dreaming up drugs that no one has ever

This week's highlight includes congrats to Omolade Otun, Chris de Graaf, Cherine Bechara, et al. for Understanding real-time kinetics to predict activity and in vivo target coverage.

We have achieved a great deal in the last decade, such as the first-ever AI-designed drug candidates

November 2021 "Cambridge’s Japanese-owned life sciences company Sosei Heptares has clinched a lucrative deal

three different binding modes: CC chemokines with deep binding, CC/CXC chemokines with shallow binding near TM5, and CX3C chemokines with shallow binding near the ECL2 hairpin. receptors - one connects the N-terminus to the extracellular tip of the seventh transmembrane helix (TM7) near the middle of the transmembrane region, and the N7.49P7.50xxY7.53 and D3.49R3.50Y3.51 motifs, located near , the inactive conformation is stabilized by the inactive configuration of the D3.49R3.50Y3.51motif near

using Cell Counting Kit-8 and colon formation, and cell migration and invasion were detected by wound healing

Although they form an ancient signaling system, there is still a great deal of variety in neuropeptides

Cary, B.P., et al., New Insights into the Structure and Function of Class B1 GPCRs.   of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real

other autoimmune diseases, (d) showed spontaneously fluctuating Ca levels from approximately normal to near

Development of Precision Medicine Platform Sosei Heptares and Neurocrine Biosciences won Top Out-Licensing Deal on the 8th annual Japan Deal of the Year Call for GPCR Papers GPCRs: Signal Transduction.

., Choi, H. J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D.

nuanced regulatory mechanism that could be crucial in contexts such as cancer progression and wound healing

Progress Parker Moss to Join Exscientia as EVP, Corporate Development Confo Therapeutics Nominated for 'Deal

Advanced Therapy Showcase in Tokyo, Japan, organized by LINK-J Jounce takes the cash under amended deal

Understanding real-time kinetics to predict activity and in vivo target coverage. Exclusive Deal for Scientists in Developing Nations If you reside and work in a developing country, complete

Septerna sells GPCR program to Vertex for $48 million Merck KGgA collaborates with Exscientia plc in deal

antagonists BenevolentAI, Exscientia on the comeback trail after securing separate AI drug discovery deals

Exclusive Deal for Scientists in Developing Nations If you reside and work in a developing country, complete

Neil Grimsey and Dr. Katarzyna Marcinkiewicz.

Neil Grimsey and Dr. Katarzyna Marcinkiewicz.

Understanding real-time kinetics to predict activity and in vivo target coverage. Exclusive Deal for Scientists Residing and Working in Developing Nations If you live and work  in a developing

Exclusive Deal for Scientists Residing and Working in Developing Nations If you live and work  in a developing reprogramming lipid metabolism via p38-SCD1 axis Methods & Updates in GPCR Research GPCRSPACE: A New GPCR Real